Characterization of a Castrate Resistant Prostate Cancer Xenograft Derived from a Patient of West African Ancestry

Here we report the establishment and characterization of a Prostate Cancer Patient Derived Explant (PCPDX) from a patient of West African ancestry with metastatic castration resistant disease. The following data represents gene expression in a series of mice carrying this PCPDX and undergoing different treatment courses. Mice were treated for 10 weeks with either Enzalutamide, Cisplatin, or Docetaxel, or appropriate vehicle controls. RNA sequencing of gene expression in mice with prostate cancer after standard of care treatment